A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study of Bifeprunox in the Treatment of Depression in Outpatients With Bipolar Disorder

Purpose:

The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.

Criteria:

Inclusion Criteria: - Diagnosis of bipolar disorder - Experiencing a depressive episode

NCT ID:

NCT00134459

Primary Contact:

Study Director
Medical Monitor, MD
Wyeth is now a wholly owned subsidiary of Pfizer

Backup Contact:

N/A

Location Contact:

Bradenton, Florida 34208
United States



There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.